Sorin launches Ovatio ICDs (implantable cardioverter defibrillators) in Japan:
This article was originally published in Clinica
Sorin Group has launched its Ovatio DR implantable cardioverter defibrillators (ICDs) in Japan. The Milan, Italy company claims that the Ovatio product line comprises the world's smallest such devices, and hence that their thinness suits for Japanese body size. The single and dual chamber models, Ovatio VR 6250 and DR 6550 ICD, have received regulatory and reimbursement approval from the Japanese health ministry (MHLW). Both models are immediately available. The dual chamber Ovatio DR includes a feature designed to reduce unnecessary stimulation in the right ventricle, thus decreasing the risk of heart failure and atrial fibrillation, as well as a component intended to protect patients from inappropriate shocks.
You may also be interested in...
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.
The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.
The pharmaceutical industry is more diverse today in terms of nationality and culture. However, there is still a lack of other types of diversity, which blocks the proactive inclusion of different perspectives. Raafi-Karim Alidina, a consultant with global diversity and inclusion consultancy Frost Included and the co-author of Building An Inclusive Organisation shares his thoughts.